Trial Profile
A Randomized, Open Label, Multicenter, Phase II, 2-Arm Study comparing the conventional 3 weekly schedule of Jevtana (Cabazitaxel) with a weekly regimen in patients with Metastastic Castration Resistant Prostate Cancer ConWeCab.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ConCab
- 20 Apr 2018 Primary endpoint (Relative cumulative dose of cabazitaxel at week 18) has not been met as per the results published in the European Journal of Cancer.
- 20 Apr 2018 Results published in the European Journal of Cancer
- 30 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.